

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 February 2025 (13.02.2025)



(10) International Publication Number
WO 2025/032220 A1

(51) International Patent Classification:

A61K 9/08 (2006.01) *A61K 47/42* (2017.01)
A61K 38/48 (2006.01) *A61K 8/00* (2006.01)
A61K 47/18 (2017.01) *A61K 8/64* (2006.01)
A61K 47/26 (2006.01) *A61Q 19/08* (2006.01)
A61K 47/36 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2024/072585

(22) International Filing Date:

09 August 2024 (09.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23190937.5 10 August 2023 (10.08.2023) EP

(71) Applicant: **MERZ PHARMA GMBH & CO. KGAA**
[DE/DE]; Eckenheimer Landstraße 100, 60318 Frankfurt
am Main (DE).

(72) Inventors: **FINK, Klaus**; c/o Eckenheimer Landstraße
100, 60318 Frankfurt am Main (DE). **TAYLOR, Harold**
Victor; c/o Eckenheimer Landstraße 100, 60318 Frankfurt
am Main (DE). **EISELE, Karl-Heinz**; c/o Eckenheimer
Landstraße 100, 60318 Frankfurt am Main (DE).

(74) Agent: **WALLINGER RICKER SCHLOTTER TOST-**
MANN PATENT- UND RECHTSANWÄLTE PART-
nerschaft MBB; Zweibrückenstraße 5 - 7, 80331 Mu-
nich (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: LIQUID BOTULINUM TOXIN FORMULATION AND USE THEREOF

(57) Abstract: The present invention relates to liquid formulations comprising (i) botulinum toxin, (ii) human serum albumin (HSA), (iii) hyaluronic acid, (iv) alditol, and optionally (v) a tonicity agent and/or (vi) a buffer agent. In a preferred embodiment, HSA has been subjected to a chelating agent. In addition, the present invention relates to the use of the liquid formulations in the treatment of therapeutic and cosmetic indications.

WO 2025/032220 A1